Date: 2015-08-26
Type of information: Construction of a production plant
Compound:
Company: Novo Nordisk (Denmark)
Therapeutic area: Metabolic diseases
Type agreement: construction of a production plant
Action mechanism:
Disease: type 1 diabetes, type 2 diabetes
Details: * On August 26, 2015, Novo Nordisk announced the company plans to invest an estimated $ 2 billion over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines. Novo Nordisk\'s current plant in Clayton, NC is today one of the company\'s strategic production sites responsible for formulation, filling and packaging of diabetes care products. The plant also assembles and packages the FlexPen® and FlexTouch® prefilled insulin device for the US market. The facilities in Clayton will produce active pharmaceutical ingredients (API) for both oral semaglutide and a range of Novo Nordisk\'s current and future GLP-1 and insulin products. The investment is estimated to create close to 700 new production and engineering jobs in Clayton where Novo Nordisk already employs more than 700 people. Novo Nordisk also plans to establish a new production facility in Måløv, Denmark for tableting and packaging of oral semaglutide and future oral products. The investment in Måløv will create an estimated 100 new jobs. In Måløv, 250 employees today produce tablets for hormone replacement therapy. The current plant is located next door to Novo Nordisk\'s largest Research & Development campus, which employs more than 2,300 employees. The final design and cost of the new production facilities will be presented for approval by the company\'s board of directors in 2016. The facilities are expected to be operational during 2020
Financial terms:
Latest news:
